Hepatic Cell News 3.05 February 15, 2019 | |
| |
TOP STORYMechanistic studies in vitro demonstrated that hepatic IRF6 directly binds to the promoter of the peroxisome proliferator-activated receptor γ (PPARγ) gene and subsequently halts the transcription of Pparγ and its target genes under physiological conditions. [Hepatology] Abstract | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)Lineage Tracing Reveals the Bipotency of SOX9+ Hepatocytes during Liver Regeneration Scientists developed a genetic tracing system to delineate the lineage potential of SOX9+ hepatocytes during liver homeostasis and regeneration. Fate-mapping data showed that SOX9+ hepatocytes respond specifically to different liver injuries, with some contributing to a substantial number of ductal cells. [Stem Cell Reports] Full Article | Graphical Abstract Investigators evaluated Axl expression in sorafenib-naive and resistant clones of epithelial and mesenchymal origin using antibody arrays and confirmed tissue expression. They tested the effect of Axl inhibition with RNA-interference and pharmacologically with R428 on a number of phenotypic assays. [Brit J Cancer] Full Article The authors discovered that in vitro, PD901 treatment strongly inhibited cholangiocarcinoma cell proliferation, and combined PD901 and MLN0128 therapy further increased growth inhibition. In vivo, treatment of PD901 alone triggered tumor regression, which was not further increased when the two drugs were administered simultaneously. [Cell Death Dis] Full Article Cell contraction and glycolysis were examined in cultured human hepatic stellate cells and mouse liver fibrosis model upon oroxylin A intervention using diversified cellular and molecular assays, as well as genetic approaches. [Cell Commun Signal] Full Article Glycoalkaloids were isolated, purified and proved to possess in vitro cytotoxicity against human liver cancer cell lines. Researchers investigated the potential mechanism of action of compounds using DNA content flow-cytometry and apoptosis/necrosis differential anaylsis using annexin-V/FITC staining. [Sci Rep] Full Article Microarray and pathway enrichment analysis revealed that MYC was a major target of 1,2,3,4,6-penta-O-galloyl-beta-D-glucopyranoside (PGG). PGG suppressed MYC mRNA and protein expression in Huh7 and Hep G2 cells in a dose- and time-dependent fashion. [Sci Rep] Full Article Researchers characterized the function of LINC00628 in hepatocellular carcinoma (HCC). The investigation revealed that LINC00628 were dramatically decreased in HCC tissues and cells, and inhibited the migration and invasion of HCC cells in vitro and in vivo. [J Cell Physiol] Abstract In both liver and non-liver cell lines, steroid A-ring reductase, 5β-reductase (AKR1D1) over-expression increased glucocorticoid clearance with a concomitant decrease in the activation of the glucocorticoid receptor and the down-stream expression of glucocorticoid target genes. Conversely, knockdown of AKR1D1 using siRNA decreased glucocorticoid clearance and reduced the generation of 5β-reduced metabolites. [J Steroid Biochem Mol Biol] Abstract Subscribe to one of our other 19 science newsletters such as Intestinal Cell News & Pancreatic Cell News. | |
| |
REVIEWSA Literature Review for the Mechanisms of Stress-Induced Liver Injury The authors summarize the mechanisms that have been proposed to be involved in stress-induced liver injury. [Brain Behav] Full Article Visit our reviews page to see a complete list of reviews in the hepatic cell research field. | |
| |
INDUSTRY NEWSConatus Pharmaceuticals Inc. announced the completion of enrollment in ENCORE-LF, a Phase IIb clinical trial evaluating emricasan, the company’s first-in-class, orally-active pan-caspase inhibitor. [Conatus Pharmaceuticals Inc.] Press Release Delcath Announces Health Authority Approval for Chemosat in Brazil Delcath Systems, Inc. announces that the company has received medical device approval for the CHEMOSAT® Hepatic Delivery System from the national health authority in Brazil. [Delcath Systems, Inc.] Press Release Gilead Sciences, Inc. announced that STELLAR-4, a Phase III, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of selonsertib, an investigational, once-daily, oral inhibitor of apoptosis signal-regulating kinase 1, in patients with compensated cirrhosis due to nonalcoholic steatohepatitis, did not meet the pre-specified week 48 primary endpoint of a ≥ 1-stage histologic improvement in fibrosis without worsening of NASH. [Gilead Sciences, Inc.] Press Release Calliditas Therapeutics Granted Orphan Drug Designation by the FDA for Primary Biliary Cholangitis Calliditas Therapeutics AB announced that the US FDA has granted orphan drug designation to the company for the treatment of primary biliary cholangitis. [Calliditas Therapeutics AB] Press Release Lipocine Inc. announced that the U.S. FDA indicated that the Phase II clinical study of LPCN 1144 in non-alcoholic steatohepatitis with biopsy confirmed NASH subjects may proceed in response to the company’s Investigational New Drug application. [Lipocine Inc.] Press Release CymaBay Therapeutics, Inc. announced that the U.S. FDA has granted Breakthrough Therapy Designation for seladelpar for the treatment of early stage primary biliary cholangitis in combination with ursodeoxycholic acid (UDCA) in adult patients with an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA. [CymaBay Therapeutics, Inc.] Press Release | |
| |
POLICY NEWSIndian Payment-for-Papers Proposal Rattles Scientists Indian scientists are criticizing a government proposal to pay graduate students who publish in select journals. They fear that it could degrade the quality of research and lead to an increase in scientific misconduct, by incentivizing publishing rather than good science. [Nature News] Editorial Hungary’s Scientists Outraged by Government Budget Grab In the cold afternoon sunshine of 12 February, hundreds of scientists and their supporters formed a human chain around the historic Hungarian Academy of Sciences building in Budapest. The gesture was one of protection. Inside, academy members were holding an emergency meeting to decide how to handle what they say is a serious a threat to the nation’s science community. [Nature News] Editorial
| |
EVENTSNEW 3rd SUNRiSE Meeting : New Advances in Cancer Stem Cells Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Senior Research Scientist – Nonalcoholic Steatohepatitis (Gilead Sciences, Inc) Postdoctoral Position – Non-Alcoholic Fatty Liver Disease (London Foundation for Liver Research) Postdoctoral Research Scientist – Cancer Biology (The Beatson Institute for Cancer Research) Assistant/Associate Professor – Cancer Biology (Virginia Commonwealth University) Postdoctoral Researcher – Cancer Biology (University of California, San Francisco) Senior Scientific Officer – Cancer Biology (Cancer Research UK Beatson Institute) Postdoctoral Researcher – Cancer Biology (University of Pennsylvania – Perelman School of Medicine) Postdoctoral Position – Nonalcoholic Steatohepatitis (University of Southern Denmark) Postdoctoral Scholar – Liver Disease (Pennsylvania State University) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Hepatic Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|